Peer-reviewed veterinary case report
Blood test for early detection and prognosis of dog mammary tumors
By Chih-Ching Wu et al.Ā·Published in Veterinary QuarterlyĀ·2025Ā·Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan, GBĀ·View original on DOAJ ā
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research ā every detail traces back to the citation above. How we work ā
Original publication title: Multiplexed immunoassay for a serum autoantibody biomarker panel in diagnostic and prognostic prediction of canine mammary tumors
- Species:
- dog
Plain-English summary
A study found that dogs with mammary tumors had higher levels of specific autoantibodies in their blood compared to healthy dogs. This test could help detect these tumors earlier, which is important since they are often diagnosed late and can be very serious. The researchers identified four autoantibodies that were significantly elevated in dogs with early-stage tumors, suggesting that this test could be useful for both diagnosing and predicting outcomes for dogs with mammary tumors. While the test showed good specificity, it still needs further development to improve its sensitivity for better early detection.
People also search for: dog mammary tumor symptoms Ā· early detection of canine mammary tumors Ā· dog cancer blood test
Abstract
Canine mammary tumor (CMT) is a prevalent and destructive disease often diagnosed at an advanced stage, leading to poor outcomes. Currently, there is a lack of effective biomarkers for early detection and prognostic prediction of CMT. To improve CMT detection, we established a multiplexed immunoassay using a fluorescence bead-based suspension array system to measure serum levels of autoantibodies against four CMT-associated proteins (AGR2, HAPLN1, IGFBP5, and TYMS) in CMT patients. Our data revealed that serum levels of the four autoantibodies (anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS) were significantly elevated in CMT patients (nā=ā158) compared to healthy individuals (nā=ā39). Notably, serum levels of anti-AGR2, anti-HAPLN1, and anti-TYMS in the dogs with stage I CMT (nā=ā56) were higher than those in the healthy group. Using a marker panel consisting of the four autoantibodies for detecting malignant CMT (nā=ā125) achieved a sensitivity of 50.4% and a specificity of 90%. Furthermore, higher levels of anti-AGR2, anti-HAPLN1, anti-IGFBP5, and anti-TYMS were associated with poorer survival in CMT patients. Collectively, we established a multiplexed immunoassay platform to detect serum autoantibodies and demonstrated that a tailored autoantibody marker panel shows potential clinical applicability for the diagnosis and prognosis of CMT.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases āOriginal publication on DOAJ: https://doi.org/10.1080/01652176.2024.2435978